Myozyme

Phase 3Completed

1 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Pompe Disease (Late-onset)

Conditions

Pompe Disease (Late-onset), Glycogen Storage Disease Type II (GSD-II), Acid Maltase Deficiency Disease, Glycogenosis 2

Trial Timeline

Dec 1, 2005 → Jun 1, 2007

NCT ID

NCT00268944

About Myozyme

Myozyme is a phase 3 stage product being developed by Sanofi for Pompe Disease (Late-onset). The current trial status is completed. This product is registered under clinical trial identifier NCT00268944. Target conditions include Pompe Disease (Late-onset), Glycogen Storage Disease Type II (GSD-II), Acid Maltase Deficiency Disease.

What happened to similar drugs?

10 of 16 similar drugs in Pompe Disease (Late-onset) were approved

Approved (10) Terminated (4) Active (5)

✅alglucosidase alfaSanofiApproved

✅Alglucosidase alfaSanofiApproved

✅alglucosidase alfaSanofiApproved

✅Myozyme® (alglucosidase alfa) + Myozyme® (alglucosidase alfa)SanofiApproved

✅ALGLUCOSIDASE ALFASanofiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (8)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00268944	Phase 3	Completed	Dec 1, 2005	Jun 1, 2007	Pompe Disease (Late-onset)
NCT00125879	Phase 2/3	Completed	Jun 1, 2005	Dec 1, 2006	Glycogen Storage Disease Type II
NCT00250939	Phase 2	Completed	Feb 1, 2005	Nov 1, 2006	Pompe Disease (Late-onset)
NCT00074932	Pre-clinical	Completed	Nov 1, 2004	Dec 1, 2006	Glycogen Storage Disease Type II
NCT00059280	Phase 2/3	Completed	Apr 1, 2003	Sep 1, 2005	Glycogen Storage Disease Type II
NCT00765414	Phase 2	Completed	Apr 1, 2003	Aug 1, 2006	Pompe Disease Late-Onset
NCT00763932	Phase 2	Completed	Apr 1, 2003	Jul 1, 2006	Pompe Disease Infantile-Onset
NCT00053573	Phase 1/2	Completed	Feb 1, 2003	Nov 1, 2006	Glycogen Storage Disease Type II

Competing Products

20 competing products in Pompe Disease (Late-onset)

See all competitors

Product	Company	Stage	Hype Score
S-606001 + Placebo	Shionogi	Phase 2	42
alglucosidase alfa	Sanofi	Approved	43
GZ402666	Sanofi	Phase 1	29
alglucosidase alfa + Placebo	Sanofi	Phase 3	40
alglucosidase alfa	Sanofi	Approved	43
glucosidase alfa	Sanofi	Pre-clinical	26
Alglucosidase alfa	Sanofi	Approved	35
Avalglucosidase Alfa	Sanofi	Phase 2	35
alglucosidase alfa	Sanofi	Approved	43
alglucosidase alfa	Sanofi	Approved	43
alglucosidase alfa	Sanofi	Pre-clinical	26
Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829)	Sanofi	Phase 3	40
Myozyme® (alglucosidase alfa) + Myozyme® (alglucosidase alfa)	Sanofi	Approved	35
ALGLUCOSIDASE ALFA	Sanofi	Approved	43
alglucosidase alfa + alglucosidase alfa	Sanofi	Approved	35
Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829)	Sanofi	Phase 2	39
Myozyme	Sanofi	Phase 2	35
Myozyme	Sanofi	Phase 2	35
recombinant human acid alpha-glucosidase (rhGAA)	Sanofi	Phase 2	35
Alglucosidase Alfa + Methotrexate + Rituximab	Sanofi	Approved	43